Investigating the efficacy and safety of Myrtus nasal spray in controlling the symptoms of patients with mild COVID-19

Investigating the efficacy and safety of herbal Myrtus nasal spray in controlling the symptoms of patients with mild COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080901001165N63

Enrollment

100

Registered

2020-10-22

Start date

2020-07-22

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Covid-19

Interventions

Intervention 1: Intervention group: Myrtus nasal spray 1 puff into each nostril every 8 hours, for 14 days (In addition to routine treatment according to the latest national guideline for the treatmen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age: equal or more than 18 years; The patient have written consciously and freely consent to participate in the study; The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19. Confirmed diagnosis of COVID-19, with RT-PCR confirmation. Less than 7 days have passed since the onset of symptoms.

Exclusion criteria

Exclusion criteria: History of allergy to this nasal spray ingredients; The patient is in another clinical trial at the same time; The patient needs to receive medical care from the inpatient care; Pregnancy; Lactation.

Design outcomes

Primary

Measure	Time frame
Clinical symptoms (dry cough). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Thermometer.	—

Measure

Time frame

Clinical symptoms (dry cough). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Thermometer.

—

Secondary

Measure	Time frame
Side effects. Timepoint: Before the intervention initiation (baseline) and day 7. Method of measurement: Physical examination.;Need to be hospitalized. Timepoint: Before the intervention initiation (baseline) and day 7. Method of measurement: Question from the patient.;Mortality. Timepoint: Day 28 from the initiation. Method of measurement: Clinical assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohamad Javad Hosseini

Bagheiat-allah University of Medical Sciences

dr_mjhosseini@yahoo.com+98 21 8245 5393

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026